Multidrogrezisztencia-vizsgálatok krónikus lymphoid leukaemiában

Translated title of the contribution: Multidrug resistance in chronic lymphocytic leukemia

Tamás Szendrei, Tamás Magyarlaki, Gábor Kovács, Ágnes Nagy, Árpád Szomor, Lenke Molnár, Mariann Dávid, Margit Tokés-Füzesi, Orsolya Rideg, László Pótó, László Pajor, Béla Kajtár, Hajna Losonczy

Research output: Contribution to journalArticle

5 Citations (Scopus)


Introduction: New prognostic factors discovered in chronic lymphocytic leukemia have recently got into the center of clinical interest. While the predictive value of cytogenetical abnormalities, immunglobulin heavy chain gene mutation status, CD38 and ZAP70 expression is already well known, the significance of multidrug resistance in chronic lymphocytic leukemia is not well characterized. Aims: The goal of this study was to characterize the multidrug resistance features in 82 patients with chronic lymphocytic leukemia at the genetical, expression- and functional level and to compare it with the patient's clinical behavior (survival and response to therapy). Methods: Light Cycler Real Time PCR based "Single Nucleotide Polymorphism" analysis of the MDR1 gene, as a biological predictor of the expression level of P-glycoprotein was tested in 66 patients with chronic lymphocytic leukemia. P-glycoprotein expression and MDR-function was detected in 82 cases by flow cytometry (by use of anti-P-glycoprotein monoclonal antibody and calcein-verapamil fimctional test). Response to therapy was analyzed by statistical Fisher-test in the treated 35 patients. The survival analysis (Log-rank test) was performed on the whole population (n = 82). Results: No significant correlation was found between the three levels of multidrug resistance (genetics, phenotype, function) in our patients with chronic lymphocytic leukemia. P-glycoprotein positive cases (n = 9) were predominantly non-responders (8/9, 89%). There must be, however, other mechanisms causing non-response (total non-responders: 13/35 treated cases). Most of P-glycoprotein negative CLL patients (n = 26) responded well (21/26, 80%) to chemotherapy (responders: 22/35 treated CLL) (p < 0,001). The tendency was the same in the average expected survival rate between P-glycoprotein positive and negative patients (84 vs 203 mounths) but the difference was not significant (p = 0,106). Conclusions: This study proved the clinical prognostic significance of P-glycoprotein expression of leukaemic cells predicting the chemotherapy response and partially estimating the general survival of patients suffering from chronic lymphocytic leukemia.

Translated title of the contributionMultidrug resistance in chronic lymphocytic leukemia
Original languageHungarian
Pages (from-to)161-167
Number of pages7
JournalOrvosi hetilap
Issue number4
Publication statusPublished - Jan 27 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Multidrug resistance in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Szendrei, T., Magyarlaki, T., Kovács, G., Nagy, Á., Szomor, Á., Molnár, L., Dávid, M., Tokés-Füzesi, M., Rideg, O., Pótó, L., Pajor, L., Kajtár, B., & Losonczy, H. (2008). Multidrogrezisztencia-vizsgálatok krónikus lymphoid leukaemiában. Orvosi hetilap, 149(4), 161-167.